Clinical trial
A Single-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Ethoximod in Healthy Subjects.
NCT06361212 is registered in ClinicalTrials.gov with Longevity Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Ethoximod in Healthy Subjects.
- Lead sponsor
- Longevity Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 1, 2022
- Completion date
- January 12, 2024
- Enrollment
- 65 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.